Cutaneous lymphoma is a type of non-Hodgkin lymphoma that starts in the skin rather than in the lymph nodes or bone marrow. It develops when white blood cells in the skin become cancerous and begin to multiply uncontrollably, forming patches, plaques, or tumors on the skin’s surface. It is relatively rare, affecting roughly 8.5 people per million in the United States each year, and its behavior is often very different from lymphomas that originate deeper in the body.
How It Differs From Other Lymphomas
The key distinction is where the cancer begins. A lymphoma is classified as “primarily cutaneous” when the cancerous cells are confined to the skin at the time of diagnosis, with no involvement of the lymph nodes, bone marrow, or internal organs. This matters because cutaneous lymphomas generally follow a different clinical course and carry a different prognosis than systemic lymphomas that happen to spread to the skin secondarily. Two patients can have skin lesions that look similar under a microscope, but if one case originated in a lymph node and the other started in the skin, the expected behavior and treatment approach may be quite different.
About 65% of cutaneous lymphomas arise from T-cells (a type of white blood cell that patrols the skin), 25% from B-cells, and a small number from natural killer cells. This breakdown shapes the two major categories: cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL).
Cutaneous T-Cell Lymphoma
CTCL is the more common form and includes several subtypes, the most well-known being mycosis fungoides and Sézary syndrome. These cancers develop from skin-homing memory T-cells, immune cells that are programmed to travel to and reside in the skin.
Mycosis Fungoides
Mycosis fungoides is the most common cutaneous lymphoma overall. It typically progresses through three recognizable stages on the skin, though not every patient advances through all of them.
- Patch stage: The earliest sign is flat, scaly patches that may look reddish or brownish. They tend to appear in areas normally covered by clothing, especially the buttocks and upper thighs. At this stage, the disease can easily be mistaken for eczema, psoriasis, or a fungal infection.
- Plaque stage: Patches become thicker and more raised, with well-defined edges. They may take on ring-like or horseshoe shapes and can appear on the face and scalp.
- Tumor stage: Firm, reddish-purple nodules develop on the skin, sometimes alongside existing patches or plaques.
Many people with early-stage mycosis fungoides live with the disease for years, sometimes decades. Patients diagnosed at the earliest stage (T1, where patches or plaques cover less than 10% of the body) have a 10-year survival rate of about 89%, which is essentially no different from the general population matched for age. When the disease covers more skin (T2, 10% or more of the body surface), the 10-year survival drops to around 78%.
Sézary Syndrome
Sézary syndrome is a more aggressive form of CTCL. It involves widespread skin redness covering 80% or more of the body, intense itching, and the presence of cancerous T-cells circulating in the bloodstream. These abnormal cells, called Sézary cells, have a distinctive appearance under the microscope, with deeply folded, wrinkled nuclei. A diagnosis typically requires at least 1,000 Sézary cells per microliter of blood along with confirmation of a matching genetic clone. Unlike mycosis fungoides, which may stay confined to the skin for a long time, Sézary syndrome is considered advanced disease at diagnosis.
Cutaneous B-Cell Lymphoma
The B-cell types account for about a quarter of all cutaneous lymphomas and are divided into three main subtypes with very different outlooks.
- Primary cutaneous follicle center lymphoma has an excellent prognosis, with about 95% of patients surviving five years or more. It often recurs on the skin but rarely spreads to internal organs.
- Primary cutaneous marginal zone lymphoma behaves similarly. Skin recurrence is common, but spread beyond the skin happens in only about 4% of cases.
- Primary cutaneous diffuse large B-cell lymphoma, leg type is the most aggressive of the three. It most often appears on the lower legs of older adults and carries a 5-year survival rate of 60 to 70%.
Symptoms Beyond the Skin
The most visible symptom is the skin lesions themselves, but many patients, particularly those with CTCL, experience severe itching that can significantly affect quality of life and sleep. This itching can be one of the most distressing parts of the disease and doesn’t always correspond to the amount of visible skin involvement. Treatments that reduce the lymphoma burden generally improve the itch, but some patients also benefit from medications that block itch signals in the nervous system, including drugs that target specific receptors involved in the itch-scratch cycle.
How It Is Diagnosed
Diagnosing cutaneous lymphoma is notoriously difficult, especially in the early stages. The patches of mycosis fungoides can look nearly identical to common skin conditions like eczema or psoriasis, both to the naked eye and under a microscope. A skin biopsy is essential, and pathologists may request additional samples from different lesion sites when the first biopsy isn’t conclusive. Many patients go through multiple biopsies over months or even years before a definitive diagnosis is made.
Beyond the biopsy, doctors use a staging system that evaluates four dimensions: T (how much skin is involved), N (whether lymph nodes are affected), M (whether the cancer has reached internal organs or bone marrow), and B (whether abnormal cells are circulating in the blood). This system, developed jointly by international lymphoma organizations, helps determine how advanced the disease is and guides treatment decisions. For skin involvement specifically, less than 10% body surface area with patches or plaques is classified as T1, 10% or more is T2, one or more tumors at least 1 centimeter across is T3, and widespread redness covering 80% or more of the body is T4.
Treatment for Early-Stage Disease
When cutaneous lymphoma is limited to the skin, treatment often focuses directly on the skin rather than the whole body. This is a major difference from many other cancers. Options include prescription topical medications, targeted ultraviolet light therapy, and localized radiation.
One well-studied skin-directed treatment is a topical chemotherapy applied directly to affected areas. In a large analysis from Stanford University, this approach produced an overall response rate of 83% across all patients, with 50% achieving a complete response (all visible disease cleared). The results were even better for patients with limited skin involvement: 93% responded, and 65% had a complete response. Fewer than 10% of patients experienced significant skin reactions from the treatment.
These therapies can control the disease for extended periods, though recurrence on the skin is common and retreatment is often part of long-term management.
Treatment for Advanced Disease
When the lymphoma spreads beyond the skin or involves the blood, systemic treatments become necessary. One specialized option for Sézary syndrome is a procedure called extracorporeal photopheresis, where blood is drawn from the patient, the white blood cells are exposed to ultraviolet light with a light-sensitizing agent, and the treated cells are returned to the body. This process triggers an immune response against the cancerous cells. Treatment typically starts weekly, then tapers to every two weeks, and eventually to monthly sessions.
Other systemic approaches vary depending on the subtype and how far the disease has progressed. The aggressive B-cell subtype (leg type) generally requires more intensive treatment than the indolent B-cell forms, which may only need localized radiation even when they recur.
Living With Cutaneous Lymphoma
For many patients, particularly those with early-stage mycosis fungoides or indolent B-cell subtypes, cutaneous lymphoma is a chronic condition managed over years rather than a rapidly progressing cancer. The earliest stage of mycosis fungoides carries survival rates comparable to the general population, and many patients manage their disease with periodic skin-directed treatments.
The outlook changes meaningfully at more advanced stages. Disease that has progressed beyond the earliest stage is associated with shorter survival, which is why ongoing monitoring for changes in skin lesions, lymph node enlargement, or new symptoms is an important part of care. The wide variation in behavior across subtypes, from the nearly benign marginal zone lymphoma to the aggressive Sézary syndrome, makes accurate classification one of the most important steps in determining what a patient can expect.